WT1 presents several characteristics of an ideal target antigen for immunotherapies [9, 10, 42, 43]; it is highly expressed in leukemia cells, compared to normal cells, and leukemia cells rely on its continuous expression [44–46] making tumor escape through antigen loss unlikely. This evidence concerns the gene WT1 and neoplasm.